Manufacturing and Analytical Services
Altasciences Completes Expansion of Research and Development Laboratory in Harleysville, Pennsylvania
Laval, Québec, August 4, 2026 — Altasciences is excited to share it has expanded the R&D laboratory at its drug product formulation and manufacturing services facility in Harleysville, Pennsylvania, adding approximately 768 square feet of new laboratory space.
The expansion brings together formulation development and analytical testing within a single laboratory. This integrated setup is designed to accelerate decision-making, streamline workflows, and strengthen collaboration across scientific disciplines.
“With this expansion, we are strengthening our focus on early-stage integration, bringing our CDMO capabilities to clients earlier in the drug development journey,” said Anuji Abraham, Senior Director, Pharmaceutical Development, CDMO Services, Altasciences. “This enhances continuity across nonclinical and clinical programs, helping clients navigate key development milestones more efficiently and effectively.”
The enhanced laboratory supports phase-appropriate, target product profile (TPP)-driven formulation screening, tailored to both therapeutic areas and routes of administration while remaining agnostic to both. Capabilities include formulation development for small molecules, peptides, and complex modalities, as well as non-GLP and GLP toxicology samples for nonclinical studies.
Advanced screening models and Integrated analytical testing support nonclinical and clinical readiness, in addition to real-time formulation decisions. By operating in a non-GLP R&D environment, clients will gain flexibility to design and optimize their products before transitioning into regulated studies.
“This expansion is not just about building additional space,” said Robert Sabelli, Co-Chief Operating Officer, Altasciences. “By continuing to invest in our team, we are growing our scientific talent and connecting our capabilities earlier in the development cycle to better support our clients—and ultimately, the patients they serve.”
About Altasciences
Altasciences is a drug development organization dedicated to safely accelerating early-phase development for biotech, biopharmaceutical, and pharmaceutical companies. By combining the scale and expertise of a large CRO/CDMO with the flexibility and personalized approach of a mid-size partner, Altasciences delivers unified solutions across nonclinical, clinical, bioanalytical, and formulation and manufacturing services. Through intentional integration and true collaboration, the company removes barriers from lead candidate selection to clinical proof-of-concept—helping sponsors save time, reduce complexity, and make confident, data-driven decisions that enable earlier returns on investment. Guided by over 30 years of experience and a commitment to quality, integrity, and partnership, Altasciences enables clients to reach critical milestones faster and with greater confidence. To learn more about Altasciences, visit altasciences.com.
Julie-Ann Cabana
Altasciences
media@altasciences.com
How Clinic-Ready Manufacturing and Adaptive Clinical Trials Can Reduce Drug Development Timelines
The complexities of active pharmaceutical ingredient (API) formulation, product testing, and documentation requirements can hinder the speed at which a promising drug candidate progresses to and through clinical trials.
The Year in Review 2025
CLINDMO: Where Clinical Innovation Meets Manufacturing Excellence
ISSUE NO. 46 – Spray-Dried Dispersions
Spray-dried dispersions (SDDs) are an effective method to improve solubility and bioavailability of your active pharmaceutical ingredient (API) in early-phase drug development. The spray drying process involves converting a liquid into a dry powder, with the resulting SDDs benefiting from improved characteristics for further developments. Spray drying can also be combined with nanomilling to further improve the bioavailability, and for flexible downstream processing.
In Issue 46 of The Altascientist, explore:
- how SDDs improve efficiency of early-phase drug development
- applications and benefits of spray drying in early-phase drug manufacturing
- advances in spray drying technology for pharmaceutical development
- the use of spray dry technology in early-phase development of proteins and peptides
- key considerations for the development of spray-dried pharmaceuticals
Altasciences At CPHI Americas 2025 | By Lisa Sanford
In the ever-changing drug development world, staying agile is essential to enabling more informed decisions, faster.
A Novel Approach for Improved Bioavailability in Solid Dosage Forms
Spray Drying Nanosuspensions
ISSUE NO. 43 — Advancing Vision Care With Formulation and Manufacture of Ocular Therapeutics
According to the WHO, at least a billion people are currently living with vision impairment from a preventable or treatable source. Precedence Research reports that the global ophthalmic drug market size is estimated to double in 10 years, from $34.6 billion in 2021 to an estimated $68.93 billion by 2030.
The development of pharmacological interventions for many of these conditions has been accelerating, supported by new delivery methods and formulation approaches. For conditions that require surgery or corrective devices, eye drops are an important part of diagnosis, and pre- and post-surgery treatment plans.
In Issue 43 of The Altascientist, we explore key considerations for ophthalmic product manufacturing, including formulation, scalability, regulatory compliance, and quality control:
- Recent developments in ophthalmic medications
- Unique barriers for drug delivery to the eye
- Common types of ocular formulations
- Formulation for effective ocular drug delivery
- Systemic exposure of topical ophthalmic preparations
- Ocular gene therapy
- Manufacturing ocular drugs for clinical trials and commercialization
- A case study